Cryoballoon ablation bests antiarrhythmics as initial therapy in paroxysmal AF: NEJM

Written By :  Dr. Nandita Mohan
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2020-12-18 09:30 GMT   |   Update On 2020-12-18 09:31 GMT

Researchers have found in a new study that as initial therapy for paroxysmal Atrial fibrillation, cryoballoon ablation bested antiarrhythmics for recurrence prevention in 2 randomized trials, EARLY-AF and STOP AF.The researchers randomly assigned 303 patients with symptomatic, paroxysmal, untreated atrial fibrillation to undergo catheter ablation with a cryothermy balloon or to...

Login or Register to read the full article

Researchers have found in a new study that as initial therapy for paroxysmal Atrial fibrillation, cryoballoon ablation bested antiarrhythmics for recurrence prevention in 2 randomized trials, EARLY-AF and STOP AF.

The researchers randomly assigned 303 patients with symptomatic, paroxysmal, untreated atrial fibrillation to undergo catheter ablation with a cryothermy balloon or to receive antiarrhythmic drug therapy for initial rhythm control. All the patients received an implantable cardiac monitoring device to detect atrial tachyarrhythmia.

The follow-up period was 12 months. The primary end point was the first documented recurrence of any atrial tachyarrhythmia (atrial fibrillation, atrial flutter, or atrial tachycardia) between 91 and 365 days after catheter ablation or the initiation of an antiarrhythmic drug whereas, the secondary end points included freedom from symptomatic arrhythmia, the atrial fibrillation burden, and quality of life, describes Andrade.
The investigators observed the following results-
a. At 1 year, a recurrence of atrial tachyarrhythmia had occurred in 66 of 154 patients (42.9%) assigned to undergo ablation and in 101 of 149 patients (67.8%) assigned to receive antiarrhythmic therapy.
b. Symptomatic atrial tachyarrhythmia had recurred in 11.0% of the patients who underwent ablation and in 26.2% of those who received antiarrhythmic drugs.
c. The median percentage of time in atrial fibrillation was 0% with ablation and 0.13% with antiarrhythmic drugs.
d. Serious adverse events occurred in 5 patients (3.2%) who underwent ablation and in 6 patients (4.0%) who received antiarrhythmic drugs.
Hence, it was concluded that "among patients receiving initial treatment for symptomatic, paroxysmal atrial fibrillation, there was a significantly lower rate of atrial fibrillation recurrence with catheter cryoballoon ablation than with antiarrhythmic drug therapy, as assessed by continuous cardiac rhythm monitoring."

For further reference log on to:

Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J, Roux JF, Yung D, Skanes A, Khaykin Y, Morillo C, Jolly U, Novak P, Lockwood E, Amit G, Angaran P, Sapp J, Wardell S, Lauck S, Macle L, Verma A; EARLY-AF Investigators. Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. N Engl J Med. 2020 Nov 16. doi: 10.1056/NEJMoa2029980. Epub ahead of print. PMID: 33197159.

Tags:    
Article Source : New England Journal of Medicine

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News